Novartis

Novartis suspends cell-therapy trials after three patient deaths

Novartis has suspended several experimental CAR-T cell therapy trials after three patients died from a rare, potentially fatal immune complication. The decision raises fresh questions about the risks and oversight of next-generation treatments for autoimmune disease.